AI assistant
Sending…
UroGen Pharma Ltd. — Director's Dealing 2022
Nov 9, 2022
32312_dirs_2022-11-09_6d745aa1-a91b-4250-9f88-4b5c50b28c7d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2022-11-08
Reporting Person: Wildman Daniel George (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-11-08 | Stock Option (right to buy) | $11.88 | A | 20000 | Acquired | 2032-11-08 | Ordinary Shares (20000) | Direct |
Footnotes
F1: The shares underlying the stock option vest in equal quarterly installments for 12 quarters
More from UroGen Pharma Ltd.
Annual Report
2026
May 27
Interim / Quarterly Report
2026
May 6
Regulatory Filings
2026
May 6
Proxy Solicitation & Information Statement
2026
Apr 30
Annual Report
2026
Mar 2
Regulatory Filings
2026
Mar 2
Regulatory Filings
2026
Mar 2
Director's Dealing
2026
Feb 27
Director's Dealing
2026
Feb 19
Director's Dealing
2026
Feb 11